2024 AMP® ALS Social Toolkit

Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis
Social Media Toolkit

Thank you for your partnership in promoting the launch of the Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis Program (AMP® ALS)

This social media toolkit provides suggested pre-scripted social media posts that your organization can leverage as appropriate for promotion on your preferred social platform. Social media graphics are also provided at the bottom.

Please follow the FNIH online on the following social channels and look for the promotion of these prestigious awards! Feel free to share, like, and comment on the posts.

Social Media Posts – Partner Organization

  • Option #1
    We’re excited to participate in the Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis (AMP® ALS) program, the largest public-private partnership of its kind to accelerate     #ALS diagnosis and treatment. Learn how we’re tackling this challenging disease together: https://fnih.org/press-release/the-foundation-for-the-national-institutes-of-health-announces-the-launch-of-a-public-private-partnership-to-accelerate-als-diagnosis-and-treatment/
  • Option #2
    ALS affects thousands of people, progressively taking away their ability to move, speak, swallow, and eventually breathe. Managed by the FNIH,     the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), the largest public-private partnership of its kind, will enable discovery and development of diagnostic tools, biomarkers, and better treatments for ALS.  Learn more 
  • Option #3
    We’re excited to participate in the Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis (AMP® ALS) program,     along with the FNIH, NIH’s National Institute of Neurological Disorders and Stroke (NINDS), and industry and non-profit partners [tag as necessary] to accelerate progress in ALS research. Our objectives are clear: expedite and enable discovery and development of diagnostic tools, biomarkers, and new treatments. Learn more about AMP ALS, the largest public-private partnership of its kind to combat this devastating disease. https://fnih.org/press-release/the-foundation-for-the-national-institutes-of-health-announces-the-launch-of-a-public-private-partnership-to-accelerate-als-diagnosis-and-treatment/

Individual supporters & PWLE (Person With Lived Experience)

Individual Supporter

  • I’m excited to support the Accelerating Medicines Partnership® Amyotrophic Lateral Sclerosis (AMP® ALS) program. ALS is a progressive disease, and patients don’t have time to wait. By uniting researchers, streamlining processes, and prioritizing patient-centered initiatives, #AMPALS aims to expedite the development of therapies that can significantly improve the lives of people with #ALS.

PWLE

  • As a person with lived experience of ALS, I am sharing my perspective on the most urgent needs of people with ALS for the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) program. This effort is dedicated to accelerating the diagnosis and treatment of ALS, a devastating neurodegenerative disease that affects 30,000 Americans and has no known cure. Learn more at [link] 

[continue to share your personal experience]

Hashtags

  • #AMPALS
  • #ALS
  • #MND
  • #BridgesToBreakthroughs

Links

Partners

  • NINDS
  • FDA
  • AbbVie
  • ALS Association 
  • ALS Therapy Development Institute
  • ALS United
  • Answer ALS
  • The Association for Frontotemporal Degeneration
  • Biogen
  • Critical Path Institute
  • Eli Lilly
  • EMD Serono
  • GSK
  • Mitsubishi Tanabe Pharma America, Inc.
  • QurAlis 
  • Target ALS

Social Handles

FNIH

NIH

  • Linkedin – https://www.linkedin.com/company/national-institutes-of-health/
  • X – @NIH
  • Instagram – @NIHGov
  • Facebook – @NIH

National Institute of Disorders and Stroke (NINDS)

  • Linkedin – https://www.linkedin.com/company/national-institute-of-neurological-disorders-and-stroke-ninds
  • X – @NIH_NINDS
  • Facebook – @NINDSBrainForLife

FDA

  • Linkedin – https://www.linkedin.com/company/fda/
  • X – @US_FDA
  • Instagram – @FDA
  • Facebook – @FDA

AbbVie

  • Linkedin – https://www.linkedin.com/company/abbvie/
  • X – @abbvie
  • Instagram – @abbvie
  • Facebook – @abbvie

ALS Association

  • Linkedin – https://www.linkedin.com/company/the-als-association/
  • X – @ alsassociation
  • Instagram – @als
  • Facebook – @alsassociation

ALS TDI

  • Linkedin – https://www.linkedin.com/company/als-therapy-development-institute/
  • X – @alstdi
  • Instagram – @alstdi
  • Facebook – @ALSTherapyDevelopmentInstitute

ALS United – See local chapter for social handles

Answer ALS

  • Linkedin – https://www.linkedin.com/company/answer-als/
  • X – @answerals
  • Facebook – @answerals

AFTD

  • Linkedin – https://www.linkedin.com/company/the-association-for-frontotemporal-degeneration/
  • X – @AFTDHope
  • Instagram – @theaftd
  • Facebook – @theaftd

Biogen

  • Linkedin – https://www.linkedin.com/company/biogen-/
  • X – @biogen
  • Facebook – @biogen

Critical Path Institute

  • Linkedin – https://www.linkedin.com/company/c-path/
  • X – @cpathinstitute
  • Facebook – @cpathinstitute

EMD Serono

  • Linkedin – https://www.linkedin.com/company/emd-serono-inc/
  • X – @emdserono
  • Facebook – @myemdserono

GSK

  • Linkedin – https://www.linkedin.com/company/gsk/
  • X – @gsk
  • Instagram – @gsk
  • Facebook – @gsk

Lilly

  • Linkedin – https://www.linkedin.com/company/eli-lilly-and-company/
  • X – @elilillyandco
  • Instagram – @elilillyco
  • Facebook – @elilillyandco

Mitsubishi Tanabe Pharma America

  • https://www.linkedin.com/company/mitsubishi-tanabe-pharma-america/
  • X – @MTPA_US
  • Facebook – @MitsubishiTanabePharmaAmerica

QurAlis

  • Linkedin – https://www.linkedin.com/company/quralis1/
  • X – @QurAlisCo

Target ALS

  • Linkedin – https://www.linkedin.com/company/target-als/
  • X – @targetals
  • Instagram – @targetals
  • Facebook – @targetals

Assets

Video

https://youtu.be/vjeR6JnL-dw

Images

Leave a comment

Your email address will not be published. Required fields are marked *